OncoMatch/Clinical Trials/NCT05961111
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Is NCT05961111 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies Recombinant oncolytic herpes simplex virus type 1 (R130) for sarcoma.
Treatment: Recombinant oncolytic herpes simplex virus type 1 (R130) — 20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Breast Carcinoma
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Glioblastoma
Melanoma
Ovarian Cancer
Endometrial Cancer
Cervical Cancer
Head and Neck Squamous Cell Carcinoma
Renal Cell Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: standard treatment
Failure of standard treatment or patient unwillingness to receive other antitumor therapy.
Cannot have received: endocrine therapy
Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.
Cannot have received: chemotherapy
Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.
Cannot have received: radiotherapy
Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.
Cannot have received: targeted therapy
Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.
Cannot have received: immunotherapy
Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.
Cannot have received: antitumor herbal therapy
Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.
Lab requirements
Blood counts
ANC ≥ 1.5 × 10^9/L, platelets ≥ 80 × 10^9/L, hemoglobin ≥ 85 g/L
Kidney function
serum creatinine (Cr) and blood urea nitrogen (BUN) within 1.5x ULN
Liver function
serum total bilirubin (TBIL) ≤ 2x ULN; ALT and AST ≤ 2.5x ULN (≤ 5x ULN with liver metastases)
laboratory tests during the screening period must meet the following requirements: a) absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L, platelets (PLT) ≥ 80 × 10^9/L, and hemoglobin (Hb) ≥ 85 g/L; b) serum creatinine (Cr) and blood urea nitrogen (BUN) within 1.5 times the upper limit of normal values; c) serum total bilirubin (TBIL) ≤ 2 times the upper limit of normal values; d) glutamic aminotransferase (ALT) and glutamic oxalacetic aminotransferase (AST) ≤ 2.5 times the upper limit of normal values; subjects with liver metastases do not exceed 5 times the upper limit of normal values; e) activated partial thromboplastin time (APTT), prothrombin time (PT) within 1.5 times the upper limit of normal values.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05961111 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior endocrine therapy, chemotherapy, radiotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages